Breakthrough Cancer Treatment Technology Offered By Doctor From Creighton University
Thursday, May 28th, 2009After being used in cancer research for long, a new way of treating cancer know as “virtual karyotyping” that can be done by re-creating chromosomes via computer technology is now available to treat cancer patients. It appears that Dr. Jill Hagenkord from the Creighton University will be the first in the world to offer such service.
From the University of Pittsburg to Creighton last year, Dr. Jill has used the method in studying cancer chromosomes for several years.
The new technology offers higher quality of image of chromosomes and cancerous tissue. Being able to target on particular damaged chromosomes, Dr. Jill and other specialist can have a better prediction on the tumor growth and determine the right drugs for the tumor. Dr. Jill added this technology is currently best for kidney, breast, blood and a few other cancers. Soon it will also be available to many more types of cancer.
According to Dr. Jared Schwartz, the president of the College of American Pathologist in North Carolina, he was familiar with the work of Dr. Jill, and called it as the way to improve cancer diagnosis and determining the right medicine. He further commented that the “trial and error” style for treating the disease has came to an end.
Dr. Jill said that she was being prepared by her trainings in molecular genetic pathology (a study of disease at the DNA level), and pathology-cancer informatics (the use of computer in analyzing huge and complex sets of biological data) to spread out the diagnosis process.
Dr. Jill Hagenkord process includes the normal laboratory works like examining a patient’s tumor sample in a microscope, place it in a test tube, and extract its DNA. After that, the DNA will be placed in a chip and will be scanned in a computer, which in turn re-create the patient’s chromosomes virtually for further study.
A similar process has also been used in discovering birth defects and cancer research at the University of Nebraska Medical Center, said Dr. Warren Sanger, UNMC’s director of human genetic laboratories. But they are not yet ready to use it for cancer patient care. Dr. Sanger commented that the process developed by D.r Jill may be able to detect some chromosomes abnormalities, but the meaning of these abnormalities to cancer diagnosis and treatment is still unclear. However, he considers it as a powerful potential tool.
At the meantime Dr. Jill agreed that her process is not yet workable to other cancer types but is found effective for others.